Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Non-Current Assets (2016 - 2025)

BioRestorative Therapies (BRTX) has disclosed Non-Current Assets for 15 consecutive years, with $935198.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non-Current Assets fell 12.15% year-over-year to $935198.0, compared with a TTM value of $4.0 million through Sep 2025, down 13.55%, and an annual FY2024 reading of $1.1 million, down 7.01% over the prior year.
  • Non-Current Assets was $935198.0 for Q3 2025 at BioRestorative Therapies, up from $918752.0 in the prior quarter.
  • Across five years, Non-Current Assets topped out at $1.3 million in Q4 2022 and bottomed at $918752.0 in Q2 2025.
  • Average Non-Current Assets over 5 years is $1.1 million, with a median of $1.1 million recorded in 2021.
  • The sharpest move saw Non-Current Assets skyrocketed 32.54% in 2022, then fell 17.75% in 2025.
  • Year by year, Non-Current Assets stood at $985538.0 in 2021, then surged by 32.54% to $1.3 million in 2022, then fell by 6.51% to $1.2 million in 2023, then decreased by 7.01% to $1.1 million in 2024, then dropped by 17.65% to $935198.0 in 2025.
  • Business Quant data shows Non-Current Assets for BRTX at $935198.0 in Q3 2025, $918752.0 in Q2 2025, and $971500.0 in Q1 2025.